NCT02538705View on ClinicalTrials.gov

Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot

NACompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 1, 2016

Study Completion Date

January 1, 2016

Conditions
Ulcers Related to Diabetic Foot Syndrome
Interventions
DRUG

Neovasculgen

Trial Locations (1)

Unknown

Human Stem Cell Institute, Moscow

Sponsors

Lead Sponsor

Artgen Biotech
All Listed Sponsors
collaborator

Ryazan State Medical University

OTHER

collaborator

Vidnoe District Hospital

UNKNOWN

lead

Artgen Biotech

OTHER

NCT02538705 - Safety and Efficacy Study of Neovasculgen (Pl-VEGF165) Gene Therapy in Patients With Diabetic Foot | Biotech Hunter | Biotech Hunter